Effect of Antidepressants on White Matter Structure

• Status: Unknown status
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects with major depression will be evaluated and intensively characterized through questionnaires, computerized cognitive evaluation and laboratory investigations. Magnetic resonance imaging will be used to document baseline white matter structure. subjects will then receive desvenlafaxine which will be adjusted as clinically indicated. After 16 weeks the evaluations will be repeated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal; Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
• Collaborator: Pfizer
• Treatments: Antidepressive Agents; Desvenlafaxine Succinate

Criteria

Inclusion Criteria:

• Major depression

• Age 18 to 55

• Hamilton grater or equal to 20

Exclusion Criteria:

• Major neurologic disorder

• Major cardiovascular disorder

• Unstable medical condition

• Significant psychiatric co-morbidity

• Current substance dependance

• Pregnancy or lactation -Treatment resistance as defined by nonresponse to 2 or more antidepressant treatments (adequate dose and duration) -